Skip to content

Enliven Therapeutics ELVN Net Change in Cash

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$635M-220%
Pfizer logo
PfizerPFE
$563M+50.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$21M-150%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
$33.44M-40.3%
Immunome logo
ImmunomeIMNM
-$70.79M-162%
Nuvation Bio logo
Nuvation BioNUVB
-$38.7M-416%

Other financials

Income statement

See full
Operating income-$27.8M+12.2%
Net income-$23.6M+17.2%
EPS (diluted)-$0.38+33.3%

Balance sheet

See full
Cash & equivalents$132.2M+30.0%
Total debt$302.0K-56.9%
Total equity$453.4M+57.3%
Total assets$464.9M+53.6%

Cash flow

See full
Operating cash flow-$19.3M+20.0%
CapEx--100%
Free cash flow-$19.3M+20.1%

Valuation

See full
Market cap$3.47B+143%
Enterprise value$3.34B+156%

Returns & leverage

See full
Return on equity-26.6%-3.5pp
Debt / equity0.0×
Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enliven Therapeutics's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Enliven Therapeutics's net change in cash?
Enliven Therapeutics (ELVN) reported net change in cash of $33.29M in Q1 2026.
How has Enliven Therapeutics's net change in cash changed year-over-year?
Enliven Therapeutics's net change in cash increased by 248.2% year-over-year, from -$22.47M to $33.29M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.